ArticleIn vitro cellular & developmental biology. Animal2026
Ginsenoside Rg3 attenuates hyperuricemia-associated AKI by upregulating CPT1A and suppressing NLRP3/Caspase-1/GSDMD-mediated pyroptosis.
Article in In vitro cellular & developmental biology. Animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia-associated acute kidney injury (HUA-AKI), a frequent complication of chronic hyperuricemia, is driven by oxidative stress, inflammation, and pyroptosis in renal tubular epithelial cells. Ginsenoside Rg3, a principal bioactive compound derived from Panax ginseng, possesses anti-inflammatory and metabolic regulatory activities; however, its therapeutic effects and underlying mechanisms in HUA-AKI remain elusive. In this study, an HUA-AKI mouse model was established via intraperitoneal injection of potassium oxonate combined with oral hypoxanthine, and an in vitro model using uric acid (UA)-stimulated HK-2 cells. Rg3 treatment markedly improved renal function, reduced tubular injury, and alleviated oxidative stress without altering serum UA levels. Transcriptomic profiling identified 229 differentially expressed genes (DEGs) reversed by Rg3, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed significant inhibition of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome and pyroptosis pathways, alongside upregulation of the carnitine palmitoyltransferase 1A (CPT1A)-mediated fatty acid oxidation pathway. Western blotting, immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA) confirmed that Rg3 upregulated CPT1A expression and suppressed activation of NLRP3, cleaved caspase‑1, gasdermin D N‑terminal fragment (GSDMD‑NT), as well as the release of interleukin (IL)-1β and IL-18 in both mouse kidney tissues and HK-2 cells. Notably, co-administration of the CPT1A inhibitor sodium taurocholate (STC) partially abolished the renoprotective effects of Rg3, as demonstrated by restored cell viability, elevated lactate dehydrogenase (LDH) release, re‑elevation of pyroptosis-related proteins and cytokines, and reappearance of membrane pore formation and rupture under transmission electron microscopy. Collectively, our findings suggest that Rg3 may ameliorate HUA‑AKI, at least in part, through CPT1A upregulation and subsequent suppression of the NLRP3/caspase-1/GSDMD axis, positioning Rg3 as a promising therapeutic candidate for HUA-AKI.
Indexed as
Identifiers
42911364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.